A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT)
Latest Information Update: 18 Apr 2024
At a glance
- Drugs Efineptakin alfa (Primary) ; Temozolomide
- Indications Glioblastoma
- Focus Therapeutic Use
- Sponsors I-MAB Biopharma
Most Recent Events
- 26 Feb 2024 Planned End Date changed from 28 Feb 2024 to 31 Dec 2024.
- 26 Feb 2024 Planned primary completion date changed from 30 Nov 2023 to 31 Dec 2024.
- 26 Feb 2024 Status changed from recruiting to active, no longer recruiting.